CoreRx
CoreRx (now Bend Bioscience) is a privately held U.S. pharmaceutical CDMO providing end-to-end small molecule drug product development and manufacturing services — formulation design, analytical, clinical, and commercial cGMP manufacturing — to pharmaceutical and biotechnology companies across three U.S. locations.
- Company typePrivate
- Founded2006
- HeadquartersClearwater, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What CoreRx does
CoreRx, Inc. (now operating under the Bend Bioscience brand following a September 2025 unification) is a privately held pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Clearwater, Florida. Founded in 2006, the company provides end-to-end small molecule drug product development services spanning formulation design, analytical and stability testing, cGMP clinical manufacturing, and commercial manufacturing. CoreRx serves pharmaceutical and biotechnology companies requiring specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release formulations, oral solids and liquids, topical formulations, and powders for inhalation. The company emphasizes a domestic U.S. manufacturing footprint across three locations in Oregon, Georgia, and Florida, positioning itself as a supply-chain-resilient alternative to offshore CDMOs. Notable specialized offerings include complex oral dosage forms, advanced spray drying capabilities (with newly expanded commercial-scale suites in Bend, Oregon), and an integrated 'High Science / High Service' model that bundles preformulation through commercial manufacturing under one organizational roof.
The business operates on a project-based professional services model, generating revenue through negotiated contracts tied to formulation development, clinical manufacturing, and commercial supply scopes. Go-to-market is B2B enterprise field sales, with direct engagement of pharmaceutical sponsors and senior presence at industry conferences such as CPHI Milan. Pricing is not publicly disclosed and is described as quote-based on project scope. In April 2024, CoreRx acquired Societal CDMO, Inc. for approximately $130 million via tender offer, delisting Societal from Nasdaq and absorbing it as a wholly owned subsidiary; the combined entity was subsequently rebranded under the unified Bend Bioscience identity in September 2025. The company currently employs 101-250 people and has raised approximately $15 million across three funding rounds between 2015 and 2019. Leadership includes Todd R. Daviau as President and CEO, Bill Reid as Executive Director and Chief Operations Officer, and Bob Berg as Chief Financial Officer.
CoreRx firmographics
Firmographics- Name
- CoreRx
- Legal name
- CoreRx, Inc.
- Website
- https://corerxpharma.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- CoreRx (now Bend Bioscience) is a privately held U.S. pharmaceutical CDMO providing end-to-end small molecule drug product development and manufacturing services — formulation design, analytical, clinical, and commercial cGMP manufacturing — to pharmaceutical and biotechnology companies across three U.S. locations.
- Ownership category
- akta.pro rank
CoreRx industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Miscellaneous Chemical Products (2890)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
Keywords
Where CoreRx is headquartered
LocationHeadquarters
- HQ city
- Clearwater
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
CoreRx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: CDMO services providing formulation development, analytical services, clinical manufacturing, and commercial manufacturing for pharmaceutical companies. Revenue generated through project-based contracts for drug development and manufacturing services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
CoreRx product offering
Product offeringCore offering
CoreRx is a pharmaceutical contract development and manufacturing organization (CDMO) providing integrated formulation development, analytical, clinical manufacturing, and commercial manufacturing services for small molecule therapeutics. Its offerings span Design, Develop, and Manufacture service tiers with specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release, oral solids, oral liquids, powders for inhalation, and topicals. Operations are supported through three U.S. manufacturing locations in Oregon, Georgia, and Florida, with newly expanded cGMP suites in Bend, Oregon.
Product overview
CoreRx operates as a pharmaceutical finished product Contract Development and Manufacturing Organization (CDMO), unified with Societal CDMO and Bend Bioscience under the Bend Bioscience brand. The company offers an integrated platform spanning Design, Develop, and Manufacture services for small molecule therapeutics. The portfolio includes specialized formulation capabilities such as Oral Bioavailability Enhancement (spray drying, particle engineering), Multiparticulates, Modified Release, Oral Dosage Form Design, Oral Solids, Oral Liquids, Powders for Inhalation, and Topicals. Service offerings encompass the full product lifecycle from Preformulation & Process Design through Analytical & Stability testing, cGMP Clinical Manufacturing, Commercial Manufacturing, Technology Transfer, Packaging, and Quality & Compliance. The company maintains world-class expertise across three U.S. locations in Oregon, Georgia, and Florida, with expanded cGMP capabilities in Bend, Oregon supporting spray drying, particle engineering, and complex oral dosage forms.
Differentiator
Problem solved
Functional benefit
Products and services
- Design Services
Companies that use CoreRx
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
CoreRx technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
CoreRx partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Starton TherapeuticsnotableDevelopment agreement for oral controlled release dosage form of STAR-LLD (lenalidomide), representing a co-development partnership for specialized pharmaceutical formulation.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
CoreRx competitors and assessment
Company assessmentDirect peers
- Recipharm: European-headquartered CDMO focused on oral solids, inhalation, and topical dosage forms, with both clinical and commercial manufacturing. Closely comparable in scope to CoreRx's specialty small molecule drug product platform.
- Aenova Group: Pharmaceutical CDMO providing solid, semi-solid, and liquid dosage form development and manufacturing, including topicals and softgel capabilities—comparable dosage form breadth to CoreRx.
- Hovione: Specialty CDMO focused on particle engineering, spray drying, and bioavailability enhancement for oral dosage forms—directly comparable to CoreRx's spray drying and particle engineering 'High Science' platform.
- Catalent: Global CDMO offering formulation development, clinical and commercial manufacturing across oral, sterile, and inhalation dosage forms—directly comparable to CoreRx's small molecule drug product CDMO platform, though at much larger scale.
- Lonza: One of the world's largest CDMOs providing small molecule and biologic drug substance and drug product services. Comparable as a full-service pharmaceutical CDMO, with overlapping oral solid dose and complex formulation capabilities.
- Almac Group: Privately held pharmaceutical CDMO offering formulation development, analytical services, and clinical/commercial manufacturing for solid oral dosage forms, with similar integrated service scope to CoreRx.
- Cambrex: CDMO providing small molecule API and finished dose development and manufacturing services, including controlled substances and high-potency compounds—comparable small molecule drug product focus.
- Societal CDMO: Now a wholly owned subsidiary of CoreRx following the $130M 2024 acquisition; provides contract development and manufacturing for complex oral, topical, and nasal dosage forms, directly overlapping with CoreRx's formulation services.
- Bend Bioscience: Bend Bioscience was combined with CoreRx and Societal CDMO under a unified brand in September 2025, and historically offered formulation and GMP spray drying services—directly comparable specialized CDMO capability, now the parent brand.
Broad incumbents
- Thermo Fisher Scientific (Patheon): Operates a major pharmaceutical services division including oral solid dose, sterile, and API CDMO services. Overlaps directly with CoreRx's small molecule drug product offering as part of a much broader life sciences services portfolio.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CoreRx social profiles
Digital presenceCoreRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
CoreRx leadership team
Management profileNumber of profiles
Profiles3 records
CoreRx subsidiaries and ownership
Company hierarchySubsidiaries1 record
CoreRx funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CoreRx M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CoreRx
What does CoreRx do?
CoreRx is a pharmaceutical contract development and manufacturing organization (CDMO) providing integrated formulation development, analytical, clinical manufacturing, and commercial manufacturing services for small molecule therapeutics. Its offerings span Design, Develop, and Manufacture service tiers with specialized capabilities in spray drying, particle engineering, oral bioavailability enhancement, multiparticulates, modified release, oral solids, oral liquids, powders for inhalation, and topicals. Operations are supported through three U.S. manufacturing locations in Oregon, Georgia, and Florida, with newly expanded cGMP suites in Bend, Oregon.
Is CoreRx a public or private company?
CoreRx is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CoreRx founded?
CoreRx was founded in 2006. It employs 101 to 250 people.
Where is CoreRx based?
CoreRx is headquartered in Clearwater, United States, in the North America region.
How does CoreRx make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are CoreRx's main competitors?
Direct peers on record are Recipharm, Aenova Group, Hovione, Catalent, Lonza, Almac Group, Cambrex, Societal CDMO and Bend Bioscience. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent.
Does CoreRx have an API?
No public API is recorded for CoreRx.
What industry is CoreRx in?
CoreRx's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 3254 and its SIC code is 2890.